Viveve Medical

Viveve Medical, Inc. engages in the design, development, manufacture, and marketing of platform medical technology. It offers cryogen-cooled monopolar radio frequency technology, which delivered through a radiofrequency generator, hand piece and treatment tip. The Viveve system is a non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company was founded on March 3, 1987 and is headquartered Englewood, CO.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q3 2021 Results - Earnings Call Transcript

Total revenue of $1.6M reported for Q3 Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4 ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended September 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. The Company's 10-Q documents will be filed on Friday, November 12, 2021, when the U.S. Securities and Exchange Commission reopens following the Veterans Day holiday.

Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 11, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Viveve to Host Conference Call on November 11, 2021 to Report Third Quarter Financial Results and Provide Corporate Update

Issuance further expands and strengthens Company's intellectual property portfolio ENGLEWOOD, CO / ACCESSWIRE / October 28, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No. 11,154,349.

Viveve Announces Issuance of New Device and Methods Patent in U.S

Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Australian Patent Office has issued Patent No. 2016324168 covering Viveve's unique method of treatment to address stress urinary incontinence (SUI) in women.

Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia

Aikido Pharma Inc.

Clovis Oncology

Biotech penny stocks are heating up right now, here's three to watch The post Are Biotech Penny Stocks Worth Buying? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are Biotech Penny Stocks Worth Buying? Check These 3 Out

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 - 15, 2021.

Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q2 2021 Results - Earnings Call Transcript

Total revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for completion in early Q4 Potential long-term reimbursement pathway established with new Category III CPT® code ENGLEWOOD, CO / ACCESSWIRE / August 12, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended June 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. "During the second quarter of 2021, Viveve continued its focus on advancing its stress urinary incontinence (SUI) clinical development program.

Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / August 5, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its second quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 12, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Viveve to Host Conference Call on August 12, 2021 to Report Second Quarter Financial Results and Provide Corporate Update

The stock price of Viveve Medical Inc (NASDAQ: VIVE) increased by over 3% pre-market. This is why it happened.

VIVE Stock Price Increases Over 3% Pre-Market: Why It Happened

ENGLEWOOD, CO / ACCESSWIRE / August 3, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Canadian Intellectual Property Office (CIPO) recently issued Canadian Patent No. 3028905 for Viveve's dual-energy technology device and method.

Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent

New code approved by American Medical Association and supported by key medical societies Long-term pathway for potential reimbursement now established for Company's dual-energy noninvasive treatment for urethral hypermobility to improve stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / July 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code for the Company's dual-energy procedure effective January 1, 2022. The new code establishes a pathway for potential reimbursement for Viveve's noninvasive treatment under evaluation in the PURSUIT trial to improve stress urinary incontinence (SUI) in women if approved by the U.S. Food and Drug Administration (FDA) for this indication.

Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure

ENGLEWOOD, CO / ACCESSWIRE / July 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, July 13 - 14, 2021. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the virtual conference.

Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference

ENGLEWOOD, CO / ACCESSWIRE / June 10, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No. 10,980,596 for Viveve's dual-energy technology device.

Viveve Announces Issuance of New Device and Methods Patent in U.S.

Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time Company encourages stockholders to cast their votes ENGLEWOOD, CO / ACCESSWIRE / June 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders for a second time due to a lack of quorum. The adjourned meeting will be held at 12:00 PM Eastern Time on Wednesday, June 23, 2021.

Viveve Announces Adjournment of Annual Meeting

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q1 2021 Results - Earnings Call Transcript

Shares of Viveve Medical (NASDAQ:VIVE) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 2.44% year over year to ($0.80), which missed the estimate of ($0.51).

Recap: Viveve Medical Q1 Earnings

Pivotal SUI PURSUIT trial enrollment underway and accelerating Total revenue of $1.5M for Q1 including sale of 2,450 consumable treatment tips Strengthened patent portfolio in key Asia Pacific markets ENGLEWOOD, CO / ACCESSWIRE / May 13, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended March 31, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. "During the first quarter of 2021, Viveve continued its focus on advancing its stress urinary incontinence (SUI) clinical development program.

Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / May 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, May 13, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Viveve To Host Conference Call on May 13, 2021 To Report First Quarter Financial Results and Provide Corporate Update

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q4 2020 Results - Earnings Call Transcript

Company continuing to advance its U.S. pivotal PURSUIT trial in stress urinary incontinence Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / March 18, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the year ended December 31, 2020. The Company will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

Viveve Reports Full Year 2020 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / March 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the virtual H.C. Wainwright Global Life Sciences Conference, March 9 - 10, 2021.

Viveve to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference

Cenovus Energy

Century Casinos

9 Meters Biopharma

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Huge Upside Potential in 5 Stocks Trading Under $10

ENGLEWOOD, CO / ACCESSWIRE / January 14, 2021 / Viveve Medical, Inc. ("Viveve") (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced the pricing of an upsized underwritten public offering of units for gross proceeds of approximately $24 Million (or $27.6 million if the underwriters exercise their option to purchase additional shares) prior to deducting underwriting discounts and commissions and offering expenses payable by Viveve. The offering is comprised of (1) 4,607,940 Class A Units, priced at a public offering price of $3.40 per Class A Unit, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at an exercise price of $3.40 per share that expires on the fifth anniversary of the date of issuance, and (2) 2,450,880 Class B Units, priced at a public offering price of $3.40 per Class B Unit, with each unit consisting of one share of Series C convertible preferred stock and one warrant to purchase one share of common stock, at an exercise price of $3.40 per share that expires on the fifth anniversary of the date of issuance.

News for Viveve Medical Stock (VIVE)